|
Clinical trials Methodology/study design
Citations 1-10 of 88 total displayed.
|
Most recent content
(26 May 2009):
|
- ARTICLES
Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year
- D. S. Knopman, C. R. Jack, Jr, J. H. Kramer, B. F. Boeve, R. J. Caselli, N. R. Graff-Radford, M. F. Mendez, B. L. Miller, and N. D. Mercaldo
Neurology 2009; 72: 1843-1849.
[Abstract]
[Full text]
[PDF]
|
Past content
(since Jan 2001):
|
- ARTICLES
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials
- Jeffrey L. Saver and Jeffrey Gornbein
Neurology 2009; 72: 1310-1315.
[Abstract]
[Full text]
[PDF]
- ARTICLES
Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs)
- W. N. Kernan, C. M. Viscoli, D. DeMarco, B. Mendes, K. Shrauger, J. L. Schindler, J. C. McVeety, A. Sicklick, D. Moalli, P. Greco, D. M. Bravata, S. Eisen, L. Resor, K. Sena, D. Story, L. M. Brass, K. L. Furie, L. Gutmann, E. Hinnau, M. Gorman, A. M. Lovejoy, S. E. Inzucchi, L. H. Young, R. I. Horwitz On behalf of the IRIS Trial Investigators
Neurology 2009; 72: 1345-1351.
[Abstract]
[Full text]
[PDF]
- VIEWS AND REVIEWS
MAO-B inhibitor know-how: Back to the pharm
- Peter A. LeWitt
Neurology 2009; 72: 1352-1357.
[Full text]
[PDF]
- EDITORIALS
Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?
- Michael S. Okun and Hubert H. Fernandez
Neurology 2009; 72: 868-869.
[Full text]
[PDF]
- EDITORIALS
Brain atrophy as an outcome measure for multiple sclerosis clinical trials: A "no-brainer"?
- Richard A. Rudick and Elizabeth Fisher
Neurology 2009; 72: 586-587.
[Full text]
[PDF]
- ARTICLES
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
- D. R. Altmann, B. Jasperse, F. Barkhof, K. Beckmann, M. Filippi, L. D. Kappos, P. Molyneux, C. H. Polman, C. Pozzilli, A. J. Thompson, K. Wagner, T. A. Yousry, and D. H. Miller
Neurology 2009; 72: 595-601.
[Abstract]
[Full text]
[PDF]
- ARTICLES
How redesigning AD clinical trials might increase study partners’ willingness to participate
- Jason Karlawish, Mark S. Cary, Jonathan Rubright, and Tom TenHave
Neurology 2008; 71: 1883-1888.
[Abstract]
[Full text]
[PDF]
- EDITORIALS
Why surrogate consent is important: A role for data in refining ethics policy and practice
- Donna T. Chen
Neurology 2008; 71: 1562-1563.
[Full text]
[PDF]
- ARTICLES
How important is surrogate consent for stroke research?
- M. L. Flaherty, J. Karlawish, J. C. Khoury, D. Kleindorfer, D. Woo, and J. P. Broderick
Neurology 2008; 71: 1566-1571.
[Abstract]
[Full text]
[PDF]
|
|
